Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FERMT2 | Q96AC1 | 2/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11935646 | 0.98 | FERMT2 (0.42) | FERMT2SHMT2RAB9AIDO1KAT2B | |
| SCHEMBL12835536 | 0.86 | FERMT2 (0.54) | FERMT2SHMT2RAB9AIDO1POLB | |
| SCHEMBL9359772 | 0.84 | KCNH3 (0.45) | SHMT2HTT | |
| SCHEMBL30046801 | 0.82 | SHMT2 (0.45) | FERMT2SHMT2RAB9APOLBALDH1A1 | |
| SCHEMBL16224813 | 0.82 | SOAT1 (0.45) | — | |
| SCHEMBL9363853 | 0.81 | PKM (0.43) | SHMT2RAB9AALDH1A1HTTMPO | |
| SCHEMBL21388179 | 0.78 | SHMT2 (0.40) | SHMT2RAB9AHTTGAA | |
| SCHEMBL5225550 | 0.77 | SHMT2 (0.44) | SHMT2RAB9APOLBALDH1A1HTT | |
| SCHEMBL1521870 | 0.77 | PKM (0.45) | FERMT2SHMT2RAB9AIDO1POLB | |
| SCHEMBL14566075 | 0.75 | SHMT2 (0.40) | FERMT2SHMT2RAB9APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723343-B2 | Adenosine A2A receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7691869-B2 | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2129220-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | King Pharmaceuticals Research and Development Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008121748-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT,INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242672-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242673-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242672-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | FERMT2 2910/4885SHMT2 412/4885RAB9A 1937/4885 |
| US-20080242673-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | FERMT2 2910/4885SHMT2 412/4885RAB9A 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.